



November 29, 2021

**U.S. Patent and Trademark Office Mails a Final Rejection of the Cook/Entox
10,894,721 Patent claims**

FOR IMMEDIATE RELEASE

Metron Nutraceuticals, LLC (Cleveland, OH) announced today that the United States Patent and Trademark Office (USPTO) issued a **final rejection** in the *ex parte* Reexamination of the **Cook/Entox 10,894,721 Patent**.

On **January 22, 2021**, Metron Nutraceuticals, LLC filed a **Request for ex parte Reexamination** with the USPTO for the U.S. Patent No. 10,894,721 issued to the “*Named Inventor*” **Christina Rahm Cook** which she has assigned to **Entox Solutions, LLC** (Austin, TX), on the basis that **all the patent claims were directed to obvious manufacturing methods relative to Metron’s own patented technology**.

Following a grant of this request, the USPTO ordered reexamination of the claims of the **Cook/Entox 10,894,721 Patent**. The USPTO initially rejected the **Cook/Entox 10,894,721 Patent** claims several months ago, and then considered rebuttal arguments from the patentee in the proceeding. Ultimately, the USPTO agreed with Metron’s understanding that the **Cook/Entox 10,894,721 Patent** claims are unpatentable and should never have been granted. The final rejection of all the patent claims was mailed by the USPTO on November 5, 2021.

“We are very pleased that the USPTO has now found the Cook/Entox 10,894,721 Patent to be obvious and unpatentable in view of the prior art, including Metron’s own patented technology. We fully expected this outcome, and now look forward to the USPTO officially canceling all claims of the Cook/Entox 10,894,721 Patent in due course,” says Dr. Nikolaos Tsirikos-Karapanos, the President of Metron Nutraceuticals, LLC.

About Metron Nutraceuticals, LLC

Metron Nutraceuticals, LLC, formed by Dr. Nikolaos Tsirikos-Karapanos in 2014 in Cleveland, Ohio, is a pioneer in the formulation and manufacture of specialized forms of natural mineral compositions for various wellness applications. Metron’s experience, innovative technology formulations, and specialized methods of manufacture have culminated in three U.S. Patents (U.S. Patent No. **9,629,874**, U.S. Patent No. **10,206,948**, and U.S. Patent No. **10,828,324**), one Patent in Japan (No. **6490807**), one Patent in Russia (No. **2744886**) as well as numerous additional International Patent Pending Applications.